P
Peter A. Forsyth
Researcher at University of South Florida
Publications - 64
Citations - 6124
Peter A. Forsyth is an academic researcher from University of South Florida. The author has contributed to research in topics: Glioma & Oncolytic virus. The author has an hindex of 33, co-authored 64 publications receiving 5140 citations. Previous affiliations of Peter A. Forsyth include Tom Baker Cancer Centre & University of Calgary.
Papers
More filters
Journal ArticleDOI
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Hussein Abdul-Hassan Tawbi,Peter A. Forsyth,Alain Algazi,Omid Hamid,F. Stephen Hodi,Stergios J. Moschos,Nikhil I. Khushalani,Karl D. Lewis,Christopher D. Lao,Michael A. Postow,Michael B. Atkins,Marc S. Ernstoff,David A. Reardon,Igor Puzanov,Ragini R. Kudchadkar,Reena Thomas,Ahmad A. Tarhini,Ahmad A. Tarhini,Anna C. Pavlick,Joel Jiang,Alexandre Avila,Sheena Demelo,Kim Margolin +22 more
TL;DR: Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.
Journal ArticleDOI
Recent progress in the battle between oncolytic viruses and tumours.
TL;DR: In the past 5 years, the field of oncolytic virus research has matured significantly and is moving past the stage of being a laboratory novelty into a new era of preclinical and clinical trials.
Journal ArticleDOI
How often are nonenhancing supratentorial gliomas malignant? A population study.
TL;DR: The presence of contrast enhancement in a brain tumor is often regarded as a sign of malignancy, but Histologic confirmation of the diagnosis is therefore important in all patients suspected of harboring a primary glial neoplasm.
Journal ArticleDOI
Health-related quality of life in patients with glioblastoma: a randomised controlled trial
Martin J.B. Taphoorn,Roger Stupp,Corneel Coens,David Osoba,Rolf D. Kortmann,Martin J. van den Bent,Warren P. Mason,René O. Mirimanoff,Brigitta G. Baumert,Elizabeth Eisenhauer,Peter A. Forsyth,Andrew Bottomley +11 more
TL;DR: Addition of temozolomide during and after radiotherapy for patients with newly diagnosed glioblastoma significantly improved survival without a negative effect on HRQOL.
Journal ArticleDOI
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Michael Weller,Thierry Gorlia,J. G. Cairncross,M. J. van den Bent,Warren P. Mason,Karl Belanger,Alba A. Brandes,Ulrich Bogdahn,David R. Macdonald,Peter A. Forsyth,Andrea O. Rossetti,Denis Lacombe,René-Olivier Mirimanoff,Charles J. Vecht,Roger Stupp +14 more
TL;DR: VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy, and future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.